- Onyx Pharmaceuticals
-
Onyx Pharmaceuticals Type Public Traded as NASDAQ: ONXX: [1]) Industry Biotechnology Founded 1992 Headquarters South San Francisco California U.S. Key people N. Anthony (Tony) Coles (CEO) Products Sorafenib (Nexavar) Employees 375 Website www.onyx-pharm.com Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. Onyx was founded in 1992 by Frank McCormick Ph.D., FRS.[1] In 2009, the company acquired Proteolix, Inc., a private biotechnology company.
Contents
Products and development
Sorafenib (co-developed and co-marketed by Bayer and Onyx as Nexavar[2]), is a drug approved for the treatment of advanced renal cell carcinoma, or advanced kidney cancer, and for the treatment of hepatocellular carcinoma, the most common form of liver cancer[3]. Sorafenib is also being evaluated in additional types of cancer, including lung[4][5], thyroid[6] and breast cancers[7].
As of September 2011, Onyx is conducting clinical trials investigating carfilzomib, a selective proteasome inhibitor that is being studied as a treatment for multiple myeloma. Clinical trials for carfilzomib include a pivotal Phase 2 clinical trial designed to seek accelerated approval in the U.S. In January 2011, the U.S. Food and Drug Administration (FDA) granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib [8].
Onyx executive leadership team
- N. Anthony (Tony) Coles, M.D.: President, Chief Executive Officer and Member of the Board
- Laura A. Brege: Executive Vice President, Corporate Affairs
- Matthew K. Fust: Executive Vice President and Chief Financial Officer
- Juergen Lasowski, PH.D.: Executive Vice President, Corporate Development and Strategy
- Ted W. Love, M.D.: Executive Vice President, Research & Development and Technical Operations
- Helen I. Torley, M.B., CH.B., M.R.C.P.: Executive Vice President and Chief Commercial Officer
- Kaye Foster-Cheek: Senior Vice President, Global Human Resources
- Suzanne M. Shema, J.D.: Senior Vice President, General Counsel
- Julianna Wood: Vice President, Public Affairs
Onyx Board of Directors
- N. Anthony (Tony) Coles, M.D.: President, Chief Executive Officer and Member of the Board
- Paul Goddard PH.D.: Lead Director, Chairman and CEO Aryx Therapeutics Inc., Chairman, AP Pharma and Director, Adolor Corporation
- Antonio J. Grillo-López, M.D.: Former Chairman, Neoplastic and Autoimmune Diseases Research Institute
- Magnus Lundberg: Chief Executive Officer, Phadia
- Corinne H. Nevinny: General Partner, LMNVC LLC
- Bill Ringo: Executive Director, Sofinnova Ventures and Senior Advisor, Barclays Capital
- Wendell Wierenga, PH.D: Executive Vice President, Research and Development, Santarus, Inc.
- Thomas G. Wiggans: Former Chairman and CEO, Peplin, Inc., and Connetics Corporation
References
- ^ "Frank McCormick Profile - Forbes.com". Forbes.com. http://people.forbes.com/profile/frank-mccormick/31320. Retrieved 2011-09-21.
- ^ "FDA Approves Nexavar for Patients with Inoperable Liver Cancer". FDA.gov. 2007-11-19. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm. Retrieved 2011-09-13.
- ^ "Liver Cancer". MD Anderson Cancer Center. http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/liver-cancer/index.html. Retrieved 2011-09-13.
- ^ "A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC. (MISSION)". ClinicalTrials.gov. 2009-03-17. http://www.clinicaltrials.gov/ct2/show/NCT00863746?term=mission&rank=1. Retrieved 2011-09-13.
- ^ "Profile:ONYX Pharmaceuticals Inc (ONXX.A)". Reuters. http://www.reuters.com/finance/stocks/companyProfile?symbol=ONXX.A. Retrieved 2011-09-13.
- ^ "Nexavar into Phase III for thyroid cancer". Pharma Times. 2009-10-27. http://www.pharmatimes.com/Article/09-10-27/Nexavar_into_Phase_III_for_thyroid_cancer.aspx. Retrieved 2011-09-13.
- ^ "UPDATE 1-Bayer starts Phase III Nexavar breast-cancer trial". Reuters. 2011-02-24. http://www.reuters.com/article/2011/02/24/bayer-onyx-idUSLDE71N0H120110224. Retrieved 2011-09-13.
- ^ "Onyx multiple myeloma drug wins FDA fast-track status". San Francisco Business Times. 2011-01-31. http://www.bizjournals.com/sanfrancisco/news/2011/01/31/onyx-multiple-myeloma-drug-wins.html. Retrieved 2011-09-21.
External links
Categories:- Companies listed on NASDAQ
- Biotechnology companies of the United States
- Companies based in San Francisco, California
Wikimedia Foundation. 2010.
